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Percutaneous vertebroplasty comprises the injection of Polymethylmethacrylate
(PMMA) bone cement into vertebrae and can be used for the treatment of com-
pression fractures of vertebrae. Metastatic bone tumors can cause such compression
fractures but are not treated when injecting PMMA-based bone cement. Hyperther-
mia of tumors can on the other hand be attained by placing magnetic nanoparticles
(MNPs) in an alternating magnetic field (AMF). Loading the PMMA-based bone
cement with MNPs could both serve vertebra stabilization and metastatic bone tumor
hyperthermia when subjecting this PMMA-MNP to an AMF. A dedicated pancake
coil is designed with a self-inductance of 10 µH in series with a capacitance of 0.1 µF
that acts as resonant inductor-capacitor circuit to generate the AMF. The thermal rise
is appraised in beef vertebra placed at 10 cm from the AMF generating circuit using
optical temperatures sensors, i.e. in the center of the PMMA-MNP bone cement, which
is located in the vicinity of metastatic bone tumors in clinical applications; and in the
spine, which needs to be safeguarded to high temperature exposures. Results show
a temperature rise of about 7 ◦C in PMMA-MNP whereas the temperature rise in
the spine remains limited to 1 ◦C. Moreover, multicycles heating of PMMA-MNP is
experimentally verified, validating the technical feasibility of having PMMA-MNP as
basic component for percutaneous vertebroplasty combined with hyperthermia treat-
ment of metastatic bone tumors. © 2016 Author(s). All article content, except where
otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1063/1.4973499]
I. INTRODUCTION
In spinal metastatic tumor disease, the vertebral body is invaded and weakened by pathological
tissue, which can lead to the collapse of the vertebral body and a progressive compression of the
spinal cord. This in turn may lead to a severe neurological function deficit. Current methods allow
either stabilization or oncological treatment of the spinal column. Vertebral body augmentation by the
injection of “cement” (polymethylmetacrylate, PMMA),1 so-called vertebroplasty (direct injection
of PMMA with high pressure device) or kyphoplasty (making a cavity in the vertebral body with a
balloon before filling it with PMMA at relatively low pressure) readily stabilizes the spine, but does
not stop tumor progression.2 Current spinal metastatic disease treatments, such as the standard and
most common neurosurgery, radiofrequency ablation3 and laser induced thermotherapy techniques4
are performed before the injection of the cement and can thus be performed only once. Surgical
procedures are possible for 1015% of the patients, but because of the frequent progression of spinal
metastases, the surgery needs to be repeated which is costly and unwanted for the patient.5 The
treatment should ideally be performed in a repetitive way, without additional invasive manipulations.
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Magnetic nanoparticles hyperthermia (MNH) consists in locally heating cancer tissue with magnetic
nanoparticles (MNPs) using an external alternating magnetic field (AMF).6,7 The heating of the tumor
tissue induces a sequence of biological processes leading to tumor cells degradation.8 Traditional bone
cement does not contain any magnetic materials but can be loaded with MNPs and clinically adminis-
tered in a minimally invasive way as it is being done in vertebroplasty or kyphoplasty. The MNPs can
then be activated through the externally generated AMF so that they heat the bone cement PMMA and
thus the surrounding biological tissue. This procedure enables on the one hand the stabilization of the
bone and on the other hand the hyperthermia of the spinal metastatic tumors.9 In order to achieve this,
a temperature increase of 6 ◦C (and for 3060 minutes of exposure) should be established in bone
metastases cells to provoke cell necrosis.10 The effectiveness of hyperthermia largely depends on the
precision of having temperature increase in the tumor and minimizing the heating of normal tissue
elsewhere.
Technical realization of the above comes with a large number of constraints. First, when heating
the tumor cells, the temperature diffusion should be controlled to not damage the healthy tissue. Partic-
ularly, in bone metastases, exposing the spine to high temperatures due to an uncontrolled heat process
may subsequently cause neuronal damage.11 The effect of the MNH on the spinal cord furthermore
depends on the exposure time and the maximum temperature reached. Animal experiments in12 indi-
cate that the maximum temperature tolerated after MNH for the spinal cord is situated in the range of
42–42,5 ◦C for exposure times of 40–60 min. In case temperatures in the range of 43 ◦C are applied, the
exposure time should be reduced to 10–30 min. The use of multicycles heating, i.e. on-off switching of
the AMF, enables more controlled thermal elevations.13 A second technical challenge is to engineer a
device capable to produce sufficient heat at a certain distance from the AMF source. The AMF can be
produced by means of a resonant inductor-capacitor (LC) circuit. The enhancement of the generated
heat can be achieved in trifold manner: increasing the MNPs concentration, applying higher cur-
rents and having an inductor specifically designed to produce sufficient AMF. The increase of MNPs
concentration has 2 constraints: the mechanical stability of the PMMA-MNP matrix and the MRI com-
patibility. The composition of the PMMA-MNP mixture has been investigated in.14 The MNPs were
dispersed in the cement matrix and it has been shown that the maximum MNPs content was around 60
wt.% vs. the total weight of the cement in order to keep mechanical stability.15 Unfortunately, such high
concentration of MNPs has considerable artefacts on MRI images whereas the diagnosis of the bone
metastases progression is done by MRI. Consequently, an appropriate concentration of the MNPs in
MNH treatment should be adjusted to the limits of the MRI procedure. A second alternative to obtain
a higher AMF is to increase the current flowing through the coil.16 Here again, there are limitations
related to Eddy current effects and the maximum current allowed by the supply. This work provides
a perspective for bone metastases MNH treatment by means of a designed pancake coil. We tested
ex-vivo the heat performance of PMMA-MNPs in beef bone samples under AMF produced by this
inductor.
II. MATERIAL AND METHODS
A. Dedicated AMF circuit
The AMF generator in our experimental setup comprises 3 main components: a power supply, a
heating station and a closed-circulating water cooling system. The power supply is a 10 kW induction
heating system able to provide an alternating current to a resonant circuit with resonance frequency
fr = 12pi√LC between 150 kHz and 400 kHz. The minimal total capacity of the capacitors in the circuit is
restricted to C = 0.1 µF. The theoretical maximum current I allowed to flow through these capacitors
is 450 A. In view of stability and safety, the current I used in practical application is limited to 200
A. By increasing the number of turns in a pancake coil, the inductance coefficient L rises while the
resonance frequency decreases. Therefore, smaller capacitances C should be used to keep the same
value of f r . A model of a pancake coil with variable number of turns N and outer radius Rmax was
implemented in Matlab (R2013a; Mathworks, Natick, MA, USA). The distance between 2 turns is
fixed to 12 mm. The AMF amplitude of the pancake coil is calculated using the Biot-Savart law
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equation:
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This equation calculates the magnetic flux density vector −→B , i.e. [Bx,By,Bz], in an arbitrary point ~r =
[x, y, z], due to the current density ~Jcoil = [Jx, Jy, Jz] in point~s= [xs, ys, zs] belonging to the coil where
a total current I is enforced. The inductance L can be calculated for a given coil as L =
∑N
k=1 ∫∫ Ak ~Bk ·d~Sk
I
with ~Bk (k = 1,. . .,N) being the magnetic induction that corresponds with the k-th turn of the coil
having a surface Ak of its cross section.
B. Ex-vivo temperature assessment using PMMA-MNP matrix
PMMA cements consist of a solid phase (polymethyl methacrylate) and a liquid phase containing
the methyl methacrylate monomer. The PMMA-MNP samples are made by mixing VertaPlexTM
radiopaque bone cement (manufactured by Stryker®) and Ferrotec EMG (Series 1500) dry iron oxide
nanoparticles. The core material of these MNPs is principally magnetite (Fe3O4) with a nominal
diameter of 10 nm. They are single domain and superparamagnetic nanoparticles with an initial
magnetic susceptibility of 0.2. The proportions by weight are 71.8 to 79.2 of iron oxide and 28.1
to 20.8 of surfactant. Having 22 wt.% of the total amount of PMMA does not significantly alter the
mechanical properties of the cement.14 The polymerization of the PMMA-MNP can be achieved
directly in the core vertebra. We used the Precision Cement Delivery System (PCD) from Stryker®
and created an artificial cavity in the beef vertebra to mimic the tumor area. The unipedicular approach
was considered by placing a needle in the right pedicle to insert the cement in the center of the core
vertebra. For having a standard measurement method that can provide reproducible results, we use
instead of a randomly-shaped cavity, a cylindrical hole which is drilled in the core of the vertebra.
During the polymerization, the PMMA-MNP mixtures are placed in cylindrical molds. The entire
bone is placed 10 cm above the AMF generating circuit and is immersed in distilled water to mimic
the biological medium, see Fig. 1. The temperature increase is measured using optical temperature
sensors in two points T1 and T2; T1 being the temperature increase in the PMMA-MNP and T2 the
temperature in the spine. As mentioned in the introduction, the temperature rise in T2 needs to remain
limited and if possible controlled by means of multicycles heating.
FIG. 1. (a) Beef bone immersed in distilled water with the PMMA-MNP sample placed at 10 cm above the AMF generating
circuit (b) Illustration of the temperatures measurements in the vertebra (T1) and in the spine (T2) (c) Frontal view of the
sample.
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III. RESULTS AND DISCUSSION
A. Coil design based on inductance and AMF amplitude calculations
Fig. 2(a) shows the calculated AMF amplitudes at a distance of z = 10 cm above the center
of a pancake coil as a function of the outer radius of the pancake coil Rmax for different number
of turns N = 6, 8 and 10 turns. The current peak value flowing through the coil is fixed to 200 A.
The AMF amplitude increases with increasing number of turn and decreases at a certain Rmax value.
The highest AMF amplitude Hmax = 2625 A/m is obtained for an inductor with N = 10 turns, Rmax
= 21 cm. The corresponding inductance of this coil is L = 29.3 µH. Nevertheless, this coil cannot
be used experimentally because of the high L value. In fact, for a fixed capacitance C = 0.1 µF the
condition of the resonance frequency f R = 160 kHz requires an inductance L = 10 µH .This is satisfied
for coil radii of 11 cm, 13 cm and 16 cm, see Fig. 2(b), corresponding to number of turns N = 10,
8 and 6, respectively. The 8 turns pancake coil with an outer radius of 13 cm seems to be the best
compromise with AMF amplitude of Hmax = 1711 A/m. On the basis of these calculations, this coil
having these specifications was made, see the insets in Fig. 3, and put in series with the C = 0.1 µF
capacitors. Inductance measurements showed that the inductance was approximately L = 10 µH and
our LC-circuit had thus a resonance frequency of about 160 kHz. The decrease in AMF along the
center line of that specific coil is reported in Fig. 3(a) as well as the decay of AMF along the radial
axis d at a distance of z = 10 cm in Fig. 3(b). The gap between 2 turns is taken as 12 mm for practical
reasons when manufacturing the coil.
B. Heating performances of the PMMA-MNP
Temperature measurement results in Fig. 4(a) show the time dependence of the heat increase
in the beef vertebra where the PMMA-MNP sample is placed at 10 cm above the center of the
FIG. 2. Calculated AMF amplitude (a) and the inductance L (b) as function of the outer radius Rmax for different number of
turns (N = 6, 8, 10), when enforcing a current with peak value I = 200 A. The gap between 2 turns is taken as 12 mm.
FIG. 3. Magnetic field calculations of an 8-turns pancake coil with Rmax = 13 cm and a gap between 2 turns of 12 mm. The
magnetic field variations are shown (a) along the center line of the coil (z-axis) and (b) for radial distance d from the center
line at a distance of z = 10 cm. The manufactured coil with z and d directions is shown in the insets.
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FIG. 4. (a) The temperature rise in the core vertebra (T1) and in the spine (T2) due to the heating of the PMMA-MNP sample
placed at 10 cm above the center of the pancake coil (I = 200 A, f R = 160 kHz). (b) The temperature rise in the core vertebra
(T1) and in the spine (T2) due to the multicycles heating of the PMMA-MNP sample placed at 10 cm above the center of the
pancake coil.
pancake coil. A temperature increase in T1 is attained of approximately Tmax = 7 ◦C above the initial
temperature T0 (here, T0 = 20 ◦C approximately) when having an AMF applied during 14 min using
the pancake coil with excitation current I = 200 A, whereas the increase of the temperature in the spine
T2 does not exceed 1 ◦C. Experiments at T0 = 37 ◦C were performed by keeping the temperature of
the water container at 37 ◦C using a 500 Watt Titanium heater and temperature controller. Since the
thermal characteristics of the materials are not significantly affected by the considered temperature
ranges (2050 ◦C), no significant differences in heat increase in Fig. 4(a) were observed. These
ex-vivo experiments demonstrate the feasibility of heating tumor cells. Note that in our experiments
there are important heat losses due to convection processes of the vertebra and PMMA-MNP in the
water. One may expect higher temperature rise in-vivo because of the biological tissue surrounding
the bone.
Fig. 4(b) displays the temperature variations during a multicycles heating process. The AMF
is switched off when T1 reaches a temperature of Tmax = T0 + 8 ◦C then switched on again after
a temperature decrease of 2 ◦C. This mimics a possible clinical procedure of MNH when having a
multicycles heating process where the temperature rise is limited in the range of 6 to 8 ◦C during
approximately half an hour (time exposure in MNH treatment) so to control the thermal elevations
inflicted to healthy tissue and spine. The graph shows that after 1 hour of applying the AMF, the
temperature increase in the spine (T2) is less than 2 ◦C. These results validate ex-vivo the techni-
cal feasibility of having PMMA-MNP material as basic component in percutaneous vertebroplasty
enabling hyperthermia treatment of metastatic bone tumors.
IV. CONCLUSION
The feasibility of having hyperthermia on the basis of PMMA-MNP samples containing 22 wt.%
iron oxide nanoparticles was tested ex-vivo in beef vertebra. A coil was designed so to enable future
animal and clinical tests; that satisfy technological constraints, i.e. the minimally allowed capacitance
of the capacitors in the resonant inductor-capacitor circuit of the AMF generator; and that generates
maximum alternating magnetic fields at a distance of 10 cm above the inductor. A dedicated pancake
coil of 8 turns with an outer radius of 13 cm was designed, having an inductance of L = 10 µH
and was placed in series with C = 0.1 µF capacitors resulting in a resonance frequency of 160 kHz.
The ex-vivo experiments show that the PMMA-MNP sample, which is in clinical application in the
vicinity of the metastatic bone tumors, heats up to 7 ◦C with a negligible temperature increase in the
spine. We moreover experimentally verified the temperate rise in the PMMA-MNP sample and in
the spine when applying on-off switched AMF, mimicking a possible clinical procedure that enables
the control of temperature elevations in healthy tissue as well as in the spine. The temperature rise in
the spine was limited to 2 ◦C whereas in the PMMA-MNP a temperature rise in the range of 68 ◦C
was established. In future research, we will gradually improve the efficiency of our equipment and
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investigate the effect of other constraints on the technical realization towards a standard therapy for
metastatic bone tumors.
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